Herantis Pharma has announced the dosing of the first healthy volunteer in the Phase 1a clinical study for HER-096.
The Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096.
“We are excited to start the Phase 1a clinical study with HER-096. This is an important milestone on our way towards developing a disease-modifying therapy for slowing or stopping the progression of Parkinson’s disease which is a major unmet clinical need today,” said Antti Vuolanto, the CEO of Herantis Pharma. “We expect to obtain the topline data by the end of 2023. If the results are in line with our expectations, we will move on to study HER-096 in Parkinson’s patients.”
The study takes place in Turku, Finland conducted by the contract research organization, CRST.